PBMs Are Stacking the Deck Against Patients and Independent Physician Practices

MedPage Today August 11, 2024
Erica R. Cohen, MD

— Infusion services and other therapies must be delivered without delay

I often hear my patients ask the same questions: Why do I need to change to another infusible biosimilar again? Why do I need to get my infusion therapy sent by a specialty pharmacy? Will I be able to continue my therapy on time?

The answers are not straightforward. The story begins in 2016 when the first biosimilar came to market in the U.S. Biosimilars are near identical copies of the original therapy with the same active ingredient, mechanism of action, and risks — but they cost less. They are made to be interchangeable with the original therapy. While this sounds reasonable at face value, the issue stems from...

Today's Sponsors

Today's Sponsor